PRC-063 Helps Treat Adults with ADHD
A team, led by Ann C. Childress, Center for Psychiatry and Behavioral Medicine, assessed the clinical efficacy, time to onset and duration of efficacy, and safety of PRC-063 compared to placebo in adult ADHD patients...PRC-063 is an extended-release formulation designed specifically to provide sustained delivery for patients with ADHD who require symptom control throughout the day.
Other Articles in this Edition
People with mental disorder diagnosis at increased risk for COVID-19 infection
Expert provides effective strategies for treating adult ADHD
ADHD in Bipolar Patients: Genetics, Diagnosis, and Treatment
Maternal Use of Valproic Acid Linked to ASD, ADHD in Offspring
Long-Acting Psychostimulants Improve Adolescent Drivers with ADHD
PRC-063 Helps Treat Adults with ADHD
David W. Goodman, MD: New Treatments Coming for ADHD
Andrew J. Cutler, MD: Screening Techniques for ADHD